Using isocapnic hyperventilation to treat methanol poisoning
The Use of Isocapnic Hyperventilation (iHV) for Treatment of Methanol Poisoned Patients
This study is testing if a breathing technique called isocapnic hyperventilation can help people with methanol poisoning recover without needing dialysis.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Oslo University Hospital Academic / other |
| Locations | 1 site (Teheran) |
| Trial ID | NCT06173817 on ClinicalTrials.gov |
What this trial studies
This clinical trial investigates the effectiveness of isocapnic hyperventilation (iHV) as a treatment for patients suffering from methanol poisoning. The approach involves administering the antidote fomepizole while patients breathe through a device that maintains normal carbon dioxide levels, allowing for the elimination of methanol from the body. Blood, urine, and breath samples will be collected to monitor methanol levels and its metabolites during the treatment. The goal is to determine if iHV can serve as a viable alternative to dialysis for methanol removal.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with methanol poisoning and exhibiting specific biochemical criteria.
Not a fit: Patients with severe acidosis requiring hemodialysis or those who are comatose will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a less invasive and more efficient method for eliminating methanol from poisoned patients.
How similar studies have performed: While the use of isocapnic hyperventilation is a novel approach, similar studies have shown promise in treating other forms of poisoning.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients, men \& women diagnosed with methanol poisoning * Serum-methanol ≥ 50 mg/dL (16 mM) * pH ≥ 7.0, and correctable by bicarbonate infusion * no (newly developed) visual disturbances Exclusion Criteria: * Acidosis requiring haemodialysis (pH \<7.0), or acidosis that is not responding in spite of aggressive buffer (bicarbonate) treatment within maximum 1-2 hours. * Comatose patients * Newly developed visual disturbances * ADH not fully blocked with antidotes, and not responding to additional dosing of fomepizole. Will be identified by a continuous or increasing anion gap (AG) or Base Excess (BE) on the blood gas machine.
Where this trial is running
Teheran
- Loghman-Hakim Hospital, — Teheran, Iran, Islamic Republic of (Recruiting)
Study contacts
- Principal investigator: Knut Erik Hovda, MD, Ph D — The Norwegian CBRNE Centre, Department of Acute Medicine, Oslo University Hospital Oslo, Norway
- Study coordinator: Knut Erik Hovda, MD, Ph D
- Email: knuterikhovda@gmail.com
- Phone: +4799618356
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.